X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE PANACEA BIOTECH SUVEN LIFE/
PANACEA BIOTECH
 
P/E (TTM) x 20.2 -21.9 - View Chart
P/BV x 4.4 2.6 169.9% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFE   PANACEA BIOTECH
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
PANACEA BIOTECH
Mar-14
SUVEN LIFE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs251149 168.7%   
Low Rs15582 188.3%   
Sales per share (Unadj.) Rs49.184.1 58.4%  
Earnings per share (Unadj.) Rs9.7-18.3 -53.1%  
Cash flow per share (Unadj.) Rs11.4-6.7 -170.1%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs60.383.7 72.0%  
Shares outstanding (eoy) m127.2861.25 207.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.4 300.9%   
Avg P/E ratio x20.9-6.3 -330.9%  
P/CF ratio (eoy) x17.8-17.2 -103.3%  
Price / Book Value ratio x3.41.4 243.9%  
Dividend payout %15.40-   
Avg Mkt Cap Rs m25,8257,074 365.1%   
No. of employees `0001.12.8 39.0%   
Total wages/salary Rs m6131,449 42.3%   
Avg. sales/employee Rs Th5,832.61,874.1 311.2%   
Avg. wages/employee Rs Th571.5527.0 108.5%   
Avg. net profit/employee Rs Th1,153.8-407.7 -283.0%   
INCOME DATA
Net Sales Rs m6,2535,154 121.3%  
Other income Rs m233100 233.2%   
Total revenues Rs m6,4855,254 123.4%   
Gross profit Rs m1,982-766 -258.6%  
Depreciation Rs m213711 30.0%   
Interest Rs m461,503 3.1%   
Profit before tax Rs m1,955-2,881 -67.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m71817 4,275.3%   
Profit after tax Rs m1,237-1,121 -110.3%  
Gross profit margin %31.7-14.9 -213.2%  
Effective tax rate %36.7-0.6 -6,298.9%   
Net profit margin %19.8-21.8 -90.9%  
BALANCE SHEET DATA
Current assets Rs m5,6223,810 147.6%   
Current liabilities Rs m1,1688,365 14.0%   
Net working cap to sales %71.2-88.4 -80.6%  
Current ratio x4.80.5 1,057.2%  
Inventory Days Days81156 52.3%  
Debtors Days Days3667 53.4%  
Net fixed assets Rs m3,32514,480 23.0%   
Share capital Rs m12761 207.7%   
"Free" reserves Rs m7,547903 835.7%   
Net worth Rs m7,6745,127 149.7%   
Long term debt Rs m145,832 0.2%   
Total assets Rs m9,13519,433 47.0%  
Interest coverage x43.2-0.9 -4,716.5%   
Debt to equity ratio x01.1 0.2%  
Sales to assets ratio x0.70.3 258.1%   
Return on assets %14.02.0 715.1%  
Return on equity %16.1-21.9 -73.7%  
Return on capital %26.03.6 715.9%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m5,0661,539 329.1%   
Fx outflow Rs m2,001942 212.4%   
Net fx Rs m3,065597 513.2%   
CASH FLOW
From Operations Rs m699599 116.7%  
From Investments Rs m-6-438 1.4%  
From Financial Activity Rs m-577-303 190.7%  
Net Cashflow Rs m116-141 -82.3%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 0.0 1.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.6 154.7%  
Shareholders   37,287 10,259 363.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare SUVEN LIFE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 19, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS